

**OPHTHALMOLOGY**  
**PAPER-IV**

**Please read carefully the important instructions mentioned on Page '1'**

- Answers to questions of Part A and part B are to be strictly attempted in separate answer sheets and the main + supplementary answer sheets used for each part must be tagged separately.
- Answers to question(s) of Part A attempted in answer sheets of Part B or vice versa shall not be evaluated.

**PART B**

- |     |  |       |
|-----|--|-------|
| 6.  | a) Define dry eyes as per DEWS 2 report.   | 3+2+5 |
|     | b) Role of anti-inflammatory agents in management of dry eyes.   |       |
|     | c) Diagnosis and management of Meibomian gland disease.  |       |
| 7.  | a) Visual prosthesis.  | 5+5   |
|     | b) Keratoprosthesis.   |       |
| 8.  | a) Ocular surface reconstruction.  | 4+6   |
|     | b) SLET - Indications, intraoperative & postoperative complications and their management.  |       |
| 9.  | a) Bevacizumab – Mechanism of action, indications and differences with other drugs of same group.  | 6+4   |
|     | b) Discuss in brief CATT 1 and CATT 2 trials.  |       |
| 10. | Enumerate and describe role of biomarkers which may be beneficial in diagnosis, pathogenesis, treatment strategies and prevention of various ocular morbidities. | 10    |

\*\*\*\*\*